Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 4Phase 1 4Phase 3 2Phase 4 1

Status

Unknown 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 65Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 41Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 30Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Triptorelin Pamoate 23Sunitinib 23Nivolumab 23Radiation 22apalutamide 21Doxorubicin 20darolutamide 18Gonadotropin-Releasing Hormone 18cabozantinib 16abiraterone 16Specimen Handling 16Radiosurgery 16Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Gene Expression Profiling × Genitourinary × Clear all
NCT01099423 2017-02-08

SURTIME

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Unknown
99 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00553124 2014-01-10

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
3,400 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡